Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$891M |
| 2 |
Union Pacific
UNP
|
+$622M |
| 3 |
Salesforce
CRM
|
+$418M |
| 4 |
Edwards Lifesciences
EW
|
+$405M |
| 5 |
lululemon athletica
LULU
|
+$347M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caterpillar
CAT
|
+$680M |
| 2 |
Texas Instruments
TXN
|
+$585M |
| 3 |
RHT
Red Hat Inc
RHT
|
+$571M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$558M |
| 5 |
Parker-Hannifin
PH
|
+$556M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.09% |
| 2 | Healthcare | 17.49% |
| 3 | Consumer Discretionary | 17.05% |
| 4 | Financials | 12.69% |
| 5 | Communication Services | 11.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Lazard
LAZ
$4.09B
| $37.3M | 0.04% |
1,011,482
-873,974
| -46% | -$34.9M |
|
252
Coca-Cola
KO
$381B
| $37M | 0.04% |
781,458
+255,629
| +49% | +$12.2M |
|
253
Energy Transfer Partners
ET
$69.6B
| $36.9M | 0.04% |
2,790,269
-311,036
| -10% | -$4.72M |
|
254
Teladoc Health
TDOC
$1.19B
| $36.8M | 0.04% |
741,589
-432,702
| -37% | -$26.5M |
|
255
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $35.9M | 0.04% |
500,000
-700,000
| -58% | -$56.4M |
|
|
CTLT
256
DELISTED
CATALENT, INC.
CTLT
| $35.7M | 0.04% |
1,144,566
+834,939
| +270% | +$32.2M |
|
257
Enterprise Products Partners
EPD
$82.5B
| $35.6M | 0.04% |
1,449,026
+102,300
| +8% | +$2.74M |
|
258
CME Group
CME
$96.1B
| $35.6M | 0.04% |
189,034
+27,252
| +17% | +$5.03M |
|
|
IMMU
259
DELISTED
Immunomedics Inc
IMMU
| $35.3M | 0.04% |
2,471,401
+309,886
| +14% | +$6.15M |
|
|
EVOP
260
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $34.3M | 0.04% |
1,389,774
-98,033
| -7% | -$2.42M |
|
261
Lamb Weston
LW
$7.36B
| $34M | 0.04% |
462,518
+67,534
| +17% | +$5.17M |
|
262
Azenta
AZTA
$1.33B
| $33.9M | 0.04% |
1,296,335
-243,870
| -16% | -$7.12M |
|
263
Merit Medical Systems
MMSI
$4.97B
| $33.9M | 0.04% |
+607,144
| New | +$36.1M |
|
264
Zoetis
ZTS
$31.9B
| $33.5M | 0.04% |
392,177
-59,516
| -13% | -$5.36M |
|
|
CONE
265
DELISTED
CyrusOne Inc Common Stock
CONE
| $33.5M | 0.04% |
633,165
+6,140
| +1% | +$351K |
|
266
Tractor Supply
TSCO
$15.8B
| $33.4M | 0.04% |
2,003,675
-215,530
| -10% | -$3.87M |
|
267
iShares Russell 1000 Growth ETF
IWF
$120B
| $33.2M | 0.04% |
1,015,284
+882,688
| +666% | +$31.1M |
|
268
Verisk Analytics
VRSK
$26.1B
| $33.2M | 0.04% |
304,241
+11,690
| +4% | +$1.37M |
|
|
GLDD
269
DELISTED
Great Lakes Dredge & Dock
GLDD
| $33M | 0.04% |
4,980,107
+60,315
| +1% | +$393K |
|
270
AMC Global Media
AMCX
$427M
| $32.8M | 0.04% |
597,521
+574,991
| +2,552% | +$33.6M |
|
271
PG&E
PCG
$39.2B
| $32.7M | 0.04% |
+1,377,072
| New | +$49.3M |
|
272
Align Technology
ALGN
$12.4B
| $32.7M | 0.04% |
156,066
+47,265
| +43% | +$11.9M |
|
|
HUD
273
DELISTED
Hudson Ltd. Class A Common Shares
HUD
| $32M | 0.04% |
1,867,996
+228,135
| +14% | +$4.49M |
|
274
Guardant Health
GH
$20.2B
| $31.7M | 0.04% |
+843,320
| New | +$31.1M |
|
275
Madrigal Pharmaceuticals
MDGL
$11.4B
| $31.7M | 0.04% |
281,071
+57,700
| +26% | +$8.93M |
|
Similar funds
Jennison Associates's Q4 2018 Portfolio in Review
As of Q4 2018, Jennison Associates held 753 positions worth $89.4B, down 18% from $109B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q4 2018 filing shows 95 new, 255 increased, 283 reduced and 113 closed positions. Its largest new stake was lululemon athletica: 2,588,881 shares worth $315M. The largest sale was Caterpillar, an estimated $680M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jennison Associates's largest Q4 2018 buy was lululemon athletica: 2,588,881 shares worth $315M.
- Jennison Associates added most to Merck in Q4 2018, an estimated $891M increase.
- Jennison Associates's biggest Q4 2018 reduction was Caterpillar, cutting an estimated $680M.
- Jennison Associates fully exited Tiffany & Co. in Q4 2018, selling an estimated $151M.
- Jennison Associates's ten largest holdings make up 30% of its $89.4B portfolio in Q4 2018.
- Jennison Associates opened 95 new positions and closed 113 in Q4 2018.
- Jennison Associates's portfolio value fell 18% quarter-over-quarter to $89.4B.
Based on Jennison Associates's 13F filing for Q4 2018, filed 6 Feb 2019.